Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
← catalyst calendarNCT04756726 · readout in 41 d
Sponsored by C4 Therapeutics, Inc. (industry) · CCCC — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
224estimated
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-04-27 | actual | When the study began enrolling |
| Primary completion | 2026-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2021-02-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Multiple Myeloma
- Lymphoma, Non-Hodgkin's
Interventions
- Drug: cemsidomide — also filed as CFT7455
- Drug: Dexamethasone Oral
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Safety and tolerability of cemsidomide
measured Baseline through 30 days after the last dose of study treatment
Phase 1: Safety and tolerability of cemsidomide in combination with dexamethasone
measured Baseline through 30 days after the last dose of study treatment
Phase 1: Maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for cemsidomide
measured Days 1-28
Phase 1: MTD or recommended RP2D for cemsidomide in combination with dexamethasone
measured Days 1-28
Phase 2: Antitumor activity of cemsidomide as a single agent
measured Baseline through 6 months after the last dose of study treatment, or until disease progression, whichever occurs first
Phase 2: Antitumor activity of cemsidomide in combination with dexamethasone
measured Baseline through 6 months after the last dose of study treatment, or until disease progression, whichever occurs first
Permalink · CCCC's whole pipeline · Catalyst calendar · Every registered study · What changed